The Journal of Practical Medicine >

2023 , Vol. 39 >Issue 16: 2029 - 2036

DOI: https://doi.org/10.3969/j.issn.1006-5725.2023.16.004

Basic Research

Preliminary study on the effects and related mechanisms of Taquimod on malignant phenotype of human glioblastoma cells

  • Xiaorui LIU ,
  • Zhongmin YUAN ,
  • Cheng ZHI ,
  • Meimei ZHANG ,
  • Xiaoshun JIAN ,
  • Huaidong. PENG
Expand
  • Department of Pharmacy，Affiliated Cancer Hospital and Institute of Guangzhou Medical University，Guangzhou 510095，China

Received date: 2023-05-24

  Online published: 2023-09-26

Fold

Abstract

Objective To investigate the effects and related mechanisms of Tasquinimod （Tasq） on malignant phenotypes such as proliferation， migration， epithelial-mesenchymal transition （EMT）， stem cell characteristics in glioblastoma multiforme（GBM）cells， so as to provide reference for preliminary experiment of Tasq as a potential drug treating GBM. Methods The effects of Tasq on the proliferation， apoptosis， migration and colony formation of GBM cell lines （U87 and U251） were evaluated by CCK?8， apoptosis staining， transwell assay and colony formation assay. The expression of apoptosis?related proteins and EMT?related proteins were detected by western blot. The effect of Tasq on spheres formation of glioma stem cell （GSC） was detected by sphere formation assay， and the expression of stem cell?related proteins in GSC were detected by immunofluorescence staining and Western blot. Results Tasq inhibited the proliferation of U87 and U251 in concentration?dependent and time?dependent manner； Tasq also inhibited the migration and colony formation of U87 and U251， and promoted its apoptosis；Tasq promoted the expression of apoptotic protein Cleaved Caspase?3 and decreased the expression of anti?apoptotic protein BCL?2， EMT?related proteins （Snail，Vimentin）. Tasq also reduced the spheroid formation ability of GSC and the expression of stem cell?related proteins （SOX2，Nestin）， the differences were statistically significant while compared with that in the control group（P < 0.01）. Conclusion Tasq inhibits proliferation， migration， colony formation of GBM cells and promoted its apoptosis in vitro. Tasq may inhibit the malignant progression of GBM cells by inhibiting EMT and stem cell characteristics.

Key words： Tasquinimod; glioblastoma cell; EMT; stem cell characteristics

Cite this article

Xiaorui LIU , Zhongmin YUAN , Cheng ZHI , Meimei ZHANG , Xiaoshun JIAN , Huaidong. PENG . Preliminary study on the effects and related mechanisms of Taquimod on malignant phenotype of human glioblastoma cells[J]. The Journal of Practical Medicine, 2023 , 39(16) : 2029 -2036 . DOI: 10.3969/j.issn.1006-5725.2023.16.004

References

1 NABORS L B， PORTNOW J， AHLUWALIA M， et al. Central Nervous System Cancers， Version 3， 2020， NCCN Clinical Practice Guidelines in Oncology［J］. J Natl Compr Canc Netw， 2020， 18（11）：1537-1570.
2 ALDAPE K， BRINDLE K M， CHESLER L， et al. Challenges to curing primary brain tumours［J］. Nat Rev Clin Oncol， 2019， 16（8）：509-520.
3 LEE S Y. Temozolomide resistance in glioblastoma multiforme［J］. Genes Dis， 2016， 3（3）：198-210.
4 BISEROVA K， JAKOVLEVS A， ULJANOVS R， et al. Cancer Stem Cells： Significance in Origin， Pathogenesis and Treatment of Glioblastoma［J］. Cells， 2021， 10（3）：621-640.
5 GEORGE S， PILI R. Tasquinimod： a novel angiogenesis inhibitor-development in prostate cancer［J］. Curr Oncol Rep， 2013， 15（2）：65-68.
6 GONG P， LIU H， LIU X， et al. Efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer： A meta-analysis of randomized controlled trials［J］. Medicine， 2018， 97（46）：e13204.
7 ISAACSJ T， ANTONY L， DALRYMPLE S L， et al. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment［J］. Cancer Res， 2013， 73（4）：1386-1399.
8 GUPTA N， Al USTWANI O， SHEN L， et al. Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer［J］. Onco Targets Ther， 2014， 7：223-234.
9 RAYMONG E， DALGLEISH A， DAMBER J E， et al. Mechanisms of action of tasquinimod on the tumour microenvironment［J］. Cancer Chemother Pharmacol， 2014， 73（1）：1-8.
10 WANG Y， XIA Y， HU K， et al. MKK7 transcription positively or negatively regulated by SP1 and KLF5 depends on HDAC4 activity in glioma［J］. Int J Cancer， 2019， 145（9）： 2496-2508.
11 DOLL J A， REIHER F K， CRAWFORD S E， et al. Thrombospondin-1， vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate［J］. Prostate， 2001， 49（4）：293-305.
12 LAWLER J. Counter regulation of tumor angiogenesis by vascular endothelial growth factor and thrombospondin-1［J］. Semin Cancer Biol， 2022， 86（Pt 2）：126-135.
13 DVORAK H F. Vascular permeability factor/vascular endothelial growth factor： a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy［J］. J Clin Oncol， 2002， 20（21）：4368-4380.
14 SHEN L， PILI R. Tasquinimod targets suppressive myeloid cells in the tumor microenvironment［J］. Oncoimmunology， 2018， 8（10）：e1072672.
15 CHENG P， CORZO C A， LUETTEKE N， et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein［J］. J Exp Med， 2008， 205（10）：2235-2249.
16 PELLETIER M， SIMARD J C， GIRARD D， et al. Quinoline-3-carboxamides such as tasquinimod are not specific inhibitors of S100A9［J］. Blood Adv， 2018， 2（10）：1170-1171.
17 CAI J Y， XU T T， WANG Y， et al. Histone deacetylase HDAC4 promotes the proliferation and invasion of glioma cells［J］. Int J Oncol， 2018， 53（6）：2758-2768.
18 ISER I C， PEREIRA M B， LENZ G， et al. The Epithelial-to-Mesenchymal Transition-Like Process in Glioblastoma： An Updated Systematic Review and In Silico Investigation［J］. Med Res Rev， 2017， 37（2）：271-313.
19 潘琦璐， 马礼兵. 上皮-间质转化在恶性肿瘤发病和侵袭转移中的作用研究进展［J］.实用医学杂志， 2020， 36（17）：2443-2447.
20 PARK I H， KANG J H， SHIN J M， et al. Trichostatin A Inhibits Epithelial Mesenchymal Transition Induced by TGF-β1 in Airway Epithelium［J］. PLoS One， 2016， 11（8）：e0162058
21 CHENG C， YANG J， LI S W， et al. HDAC4 promotes nasopharyngeal carcinoma progression and serves as a therapeutic target［J］. Cell Death Dis， 2021， 12（2）：137.
22 YABO Y A， NICLOU S P， GOLEBIEWSKA A. Cancer cell heterogeneity and plasticity： A paradigm shift in glioblastoma［J］. Neuro Oncol， 2022， 24（5）：669-682.
23 LAN X， J?RG D J， CAVALLI F M G， et al. Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy［J］. Nature， 2017， 549（7671）：227-232.
Options
Outlines

/

〈 〉